Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Pharma CEO On Star Products, Pricing And Rebates

Executive Summary

Paul Hudson, CEO, Novartis Pharmaceuticals, was recently in India along with the executive leadership team of the Swiss multinational. In a wide-ranging exclusive interview with Scrip, he discussed Cosentyx’s edge over its competition, Entresto’s “incredibly bright future”, including in emerging markets like India, and why transparency on the scale of rebates in the US is "overdue."

Advertisement

Related Content

Revolving Door: Novartis India Managing Director Quits
India Rolls Out Modicare - Can It Redefine Healthcare Access, Market Potential?
Cosentyx Carries Novartis Sales But Kymriah Manufacturing Gives Cause For Concern
India’s Big AI 'Garage' Ambition – Can It Get The Mechanics Running ?
Real World Data Helping To Drive Rise Of Novartis' Entresto
What ‘Modicare’ May Mean (Or Not) For Pharma In India

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123733

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel